The GOLGA3 Knockout SK-HEP-1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population that enables loss-of-function studies of the GOLGA3 gene in a human hepatic endothelial-like model. This polyclonal knockout product, generated by CRISPR/Cas9-mediated gene disruption, offers a heterogeneous population of edited cells, capturing the complexity of genetic perturbation without clonal selection. The constitutive disruption of the GOLGA3 locus allows researchers to investigate its cellular functions in a physiologically relevant context, bypassing the limitations of transient silencing approaches.
SK-HEP-1 is a human hepatic adenocarcinoma cell line originally derived from the ascites of a patient with liver adenocarcinoma. Despite its tumor origin, SK-HEP-1 exhibits an endothelial-like phenotype and is widely employed as an in vitro model for hepatic vascular biology and tumor angiogenesis. Its dual characteristics make it particularly valuable for studying the intersection of cancer cell signaling and vascular functions, including Golgi-mediated secretory pathways that influence endothelial cell behavior and tumor microenvironment interactions.
GOLGA3 encodes a member of the golgin family of coiled-coil proteins, which localizes to the cis-Golgi network and is critical for maintaining Golgi stack architecture and tethering transport vesicles. It functions in membrane trafficking by interacting with key Golgi matrix proteins such as GOLGA2 (GM130) and GORASP1 (GRASP65), as well as RAB GTPases, to facilitate vesicle docking and fusion. GOLGA3 activity is regulated by mitotic kinases: CDK1 phosphorylates GOLGA3 during mitosis to promote Golgi disassembly and reassembly, while upstream PI3K/AKT signaling converges on mTOR and cyclin B?CCDK1 to coordinate Golgi dynamics with cell cycle progression. Downstream, GOLGA3 influences GM130 and GRASP65 localization, vesicle trafficking protein distribution, and, indirectly, apoptotic signaling. Disruption of GOLGA3 thus impairs Golgi ribbon integrity and the ordered vesicular transport essential for protein secretion, receptor presentation, and intracellular signaling.
In the SK-HEP-1 host background, GOLGA3 knockout represents a powerful tool to dissect Golgi-dependent processes in hepatic endothelial-like cells. As these cells exhibit angiogenic properties, loss of GOLGA3 may perturb the trafficking of pro-angiogenic factors and cell surface receptors, thereby affecting endothelial differentiation, migration, and tube formation. Moreover, the intersection with liver cancer biology makes this model suitable for examining how Golgi structural defects modulate tumor cell proliferation, survival, and responses to apoptotic stimuli, providing a platform to study the role of the Golgi in hepatocarcinogenesis and vascular remodeling.
Typical research applications include immunofluorescence microscopy to monitor alterations in Golgi morphology using markers such as GM130, western blotting to assess GOLGA3 and its interacting partners, and flow cytometry to quantify apoptosis. Functional assays such as cell proliferation and migration analyses can be combined with pharmacological challenge using Golgi-disrupting agents (e.g., brefeldin A) to evaluate drug sensitivity and resistance mechanisms. This knockout model is also amenable to live-cell imaging of vesicle trafficking and high-content screening for modulators of Golgi function. For additional technical specifications, protocols, or ordering details, please contact Ascent Research.
